The ARFGEF family, short for ADP-ribosylation factor guanine nucleotide exchange factors, encompasses a group of proteins that are key regulators of vesicle trafficking within cells. These proteins function primarily as guanine nucleotide exchange factors (GEFs) for ADP-ribosylation factors (ARFs), which are small GTP-binding proteins involved in vesicle formation and transport. ARFGEFs catalyze the exchange of GDP for GTP on ARFs, activating them to initiate the budding of transport vesicles from various membranes, including the Golgi apparatus and the endoplasmic reticulum. Members of the ARFGEF family, such as BIG1, BIG2 and BIG3, are particularly important in the regulation of vesicle trafficking in the secretory pathway, which is crucial for the transport of proteins and lipids throughout the cell. Dysregulation of ARFGEF function has been implicated in several diseases, including neurological disorders and cancer, due to their role in intracellular transport and signaling.
Targeting ARFGEFs (ADP-ribosylation factor guanine nucleotide exchange factors) with small molecules allows for a direct investigation into the molecular mechanisms of vesicle trafficking and membrane dynamics in cells. By inhibiting or disrupting ARFGEF activity, these small molecules can help delineate the specific roles of ARFGEFs in processes like protein and lipid transport, Golgi apparatus function, and cell signaling. This approach not only aids in understanding the fundamental aspects of cell biology but also provides insights into targeting of ARFGEFs in diseases where their dysregulation is a contributing factor, such as in certain cancers and neurological disorders.
VER TAMBIÉN ....
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | ¥338.00 ¥587.00 ¥1376.00 ¥4140.00 | 25 | |
Se sabe que inhibe la función de los ARFGEF, incluidos BIG1 y BIG2, al estabilizar su interacción con los ARF en su estado unido a GDP, lo que altera la estructura y la función del Golgi. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | ¥2110.00 ¥7559.00 | 11 | |
Inhibe específicamente ARFGEF1 (BIG1) y ARFGEF2 (BIG2), afectando al transporte retrógrado de Golgi a ER mediado por ARF. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | ¥3080.00 | 6 | |
Aunque su diana principal son las citohesinas (otro subgrupo de ARFGEFs), también puede afectar a los ARFGEFs de la familia BIG debido a la similitud de su mecanismo. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | ¥982.00 ¥3182.00 | 1 | |
Al dirigirse al complejo Exocyst, afecta indirectamente a procesos regulados por ARFGEFs, incluido el tráfico de vesículas. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | ¥1636.00 ¥4987.00 | 64 | |
Conocido por sus propiedades disruptoras de la actina, afecta indirectamente al tráfico de vesículas, pudiendo afectar a procesos regulados por ARFGEF. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | ¥1512.00 ¥5664.00 | 7 | |
Un inhibidor de Cdc42, que afecta indirectamente a las vías que implican ARFGEFs. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | ¥4062.00 | ||
Inhibe principalmente la endocitosis mediada por clatrina, pero podría afectar indirectamente a las funciones del ARFGEF. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | ¥3723.00 | 1 | |
Un inhibidor de p97/VCP que puede afectar indirectamente a la función de los ARFGEFs, particularmente en el contexto de la degradación asociada al RE. | ||||||